Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
01.12.21
/
0%
€4.85
Target price
01.12.22
-
Performance (%)
-53.67%
End price
02.12.22
€2.25
Summary
This prediction ended on 02.12.22 with a price of €2.25. Massive losses of -53.67% were the result for the BUY prediction by Maxi_Scalibusa. This prediction was marked as speculative and is excluded from Maxi_Scalibusa's performance statistics.Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Arbutus Biopharma Corp. | 0.756% | 0.756% | 82.893% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model